Skip to main content
Erschienen in: Surgery Today 10/2012

01.10.2012 | Case Report

Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case

verfasst von: Takafumi Watanabe, Takaki Yoshikawa, Yoichi Kameda, Toru Aoyama, Tsutomu Hayashi, Takashi Ogata, Haruhiko Cho, Akira Tsuburaya, Satoshi Morita, Yumi Miyashita, Junichi Sakamoto

Erschienen in: Surgery Today | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

We report a case of advanced gastric carcinoma treated successfully by four courses of neoadjuvant chemotherapy (NAC) with paclitaxel and cisplatin. The patient was a 43-year-old man with advanced gastric cancer, clinically diagnosed as P0H0M0CY0T3N2, which had invaded the upper body of the stomach and esophagus. He was entered into a clinical trial and received the following NAC regimen: paclitaxel 80 mg/m2, and cisplatin 25 mg/m2, on days 1, 8, and 15, followed by a rest on day 22, as one course. The lymph nodes had reduced in size to 59% after two courses and to 40% after four courses, with no sign of severe toxicity. Subsequently, he underwent D2 total gastrectomy with pancreatico-splenectomy. On microscopic examinations, no tumor cells were detected in the ulcer scar of the resected stomach or the regional lymph nodes. Thus, we discuss the potential of long-term NAC, especially for responders to two initial courses.
Literatur
1.
Zurück zum Zitat Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274–5.CrossRef Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274–5.CrossRef
2.
Zurück zum Zitat Díaz de Liaño A, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96–102. Díaz de Liaño A, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96–102.
3.
Zurück zum Zitat Ott K, Lordick F, Hermann K, Krause B-J, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9.CrossRefPubMed Ott K, Lordick F, Hermann K, Krause B-J, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9.CrossRefPubMed
4.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
5.
Zurück zum Zitat Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40(4):295–300.CrossRefPubMed Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40(4):295–300.CrossRefPubMed
6.
Zurück zum Zitat Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015–22.CrossRefPubMed Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015–22.CrossRefPubMed
7.
Zurück zum Zitat Yoshikawa T, Omura K, Kobayashi O, Nishimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546–51.CrossRefPubMed Yoshikawa T, Omura K, Kobayashi O, Nishimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546–51.CrossRefPubMed
8.
Zurück zum Zitat Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–9.CrossRefPubMed Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–9.CrossRefPubMed
9.
Zurück zum Zitat Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9:129–35.CrossRefPubMed Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9:129–35.CrossRefPubMed
10.
Zurück zum Zitat Sakurai K, Yamashita Y, Shimizu S, Yoshida K, FDukuoka T, Xiang Z, et al. A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks. Jpn J Cancer Chemother. 2010;37:315–8. Sakurai K, Yamashita Y, Shimizu S, Yoshida K, FDukuoka T, Xiang Z, et al. A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks. Jpn J Cancer Chemother. 2010;37:315–8.
11.
Zurück zum Zitat Mori S, Kishimoto H, Tauchi K, Higuchi K. Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006;9:136–9.CrossRefPubMed Mori S, Kishimoto H, Tauchi K, Higuchi K. Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006;9:136–9.CrossRefPubMed
12.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.CrossRefPubMed Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10–24.CrossRefPubMed
13.
Zurück zum Zitat Nagata N, Kimura M, Hirabayashi N, Tsuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846–50.PubMed Nagata N, Kimura M, Hirabayashi N, Tsuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846–50.PubMed
14.
Zurück zum Zitat Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369–72.CrossRefPubMed Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369–72.CrossRefPubMed
15.
Zurück zum Zitat Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG0002). Gastric Cancer. 2009;12:37–42.CrossRefPubMed Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG0002). Gastric Cancer. 2009;12:37–42.CrossRefPubMed
16.
Zurück zum Zitat Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMed Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMed
17.
Zurück zum Zitat Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69–78.CrossRefPubMed Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69–78.CrossRefPubMed
18.
Zurück zum Zitat Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.CrossRefPubMedPubMedCentral Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.CrossRefPubMed Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.CrossRefPubMed
Metadaten
Titel
Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case
verfasst von
Takafumi Watanabe
Takaki Yoshikawa
Yoichi Kameda
Toru Aoyama
Tsutomu Hayashi
Takashi Ogata
Haruhiko Cho
Akira Tsuburaya
Satoshi Morita
Yumi Miyashita
Junichi Sakamoto
Publikationsdatum
01.10.2012
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 10/2012
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0155-3

Weitere Artikel der Ausgabe 10/2012

Surgery Today 10/2012 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Metformin rückt in den Hintergrund

24.04.2024 DGIM 2024 Kongressbericht

Es hat sich über Jahrzehnte klinisch bewährt. Doch wo harte Endpunkte zählen, ist Metformin als alleinige Erstlinientherapie nicht mehr zeitgemäß.

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

24.04.2024 DGIM 2024 Kongressbericht

Unerkannte Herzmuskelentzündungen infolge einer Virusinfektion führen immer wieder dazu, dass junge, gesunde Menschen plötzlich beim Sport einen Herzstillstand bekommen. Gerade milde Herzbeteiligungen sind oft schwer zu diagnostizieren – speziell bei Leistungssportlern. 

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.